On-Demand CME Videos

Liberating Patients from Prurigo Nodularis One Itch at a Time: Online CME Activity


This activity was recorded at the 2023 Winter Clinical Dermatology Conference-Hawaii on January 16, 2023.

CME Satellite Symposium: 

 Liberating Patients from Prurigo Nodularis One Itch at a Time

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. 


In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

February 10, 2023

Expiration Date:

February 10, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Cite strategies to diagnose patients with prurigo nodularis

  • Overview on how biologics target the prurigo nodularis disease pathway

  • Examine the clinical trial data for emerging therapies to treat prurigo nodularis

  • Identify strategies to incorporate emerging therapies for prurigo into clinical practice

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Raj Chovatiya, MD, PhD

Assistant Professor, Director of Center for Eczema and Itch 
Northwestern University Feinberg School of Medicine
Chicago, IL

Brian Kim, MD

Mount Sinai Icahn School of Medicine
New York, NY
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers


In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Raj Chovatiya, MD, PhD

Consultant: AbbVie, Arcutis, Arena, Argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, L’Oréal, National Eczema Association, Pfizer Inc., Regeneron, Sanofi, and UCB

Speakers’ Bureau or Honoraria: AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer Inc., Regeneron, Sanofi, and UCB

Brian S. Kim, MD

Grant/Research Support: LEO Pharma, Cara Therapeutics

Consultant: AbbView, Almirall, BMS, Pfizer, Regeneron, IncyteSano

Intellectual Property Rights: JAK Inhibitors for Itch

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.


The leading platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved